- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Novo Nordisk and Oxford University Collaborate on Diabetes Research
January 31, 2017
The University of Oxford (UK) and Novo Nordisk have announced a research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford.
The Novo Nordisk Research Centre Oxford will employ up to 100 Novo Nordisk researchers, based in an Oxford University research centre. The total investment from Novo Nordisk is expected to be around 1 billion Danish kroner ($144 million) over a period of 10 years. The centre will focus on innovation within early stage research that has potential to substantially impact future treatment of type 2 diabetes and its complications.
The collaboration will actively seek to encourage cross-fertilization of ideas between academic researchers from the University of Oxford and researchers employed by Novo Nordisk with funds to sponsor the collaborative research.
Novo Nordisk and University of Oxford have had a collaboration since 2013 through the International Postdoctoral Fellowship Program.
